Apyrase treatment of myocardial infarction according to a clinically applicable protocol fails to reduce myocardial injury in a porcine modelReportar como inadecuado




Apyrase treatment of myocardial infarction according to a clinically applicable protocol fails to reduce myocardial injury in a porcine model - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Cardiovascular Disorders

, 10:1

First Online: 04 January 2010Received: 08 October 2009Accepted: 04 January 2010DOI: 10.1186-1471-2261-10-1

Cite this article as: van der Pals, J., Koul, S., Götberg, M.I. et al. BMC Cardiovasc Disord 2010 10: 1. doi:10.1186-1471-2261-10-1

Abstract

BackgroundEctonucleotidase dependent adenosine generation has been implicated in preconditioning related cardioprotection against ischemia-reperfusion injury, and treatment with a soluble ectonucleotidase has been shown to reduce myocardial infarct size IS when applied prior to induction of ischemia. However, ectonucleotidase treatment according to a clinically applicable protocol, with administration only after induction of ischemia, has not previously been evaluated. We therefore investigated if treatment with the ectonucleotidase apyrase, according to a clinically applicable protocol, would reduce IS and microvascular obstruction MO in a large animal model.

MethodsA percutaneous coronary intervention balloon was inflated in the left anterior descending artery for 40 min, in 16 anesthetized pigs 40-50 kg. The pigs were randomized to 40 min of 1 ml-min intracoronary infusion of apyrase 10 U-ml, n = 8 or saline 0.9 mg-ml, n = 8, twenty minutes after balloon inflation. Area at risk AAR was evaluated by ex vivo SPECT. IS and MO were evaluated by ex vivo MRI.

ResultsNo differences were observed between the apyrase group and saline group with respect to IS-AAR 75.7 ± 4.2% vs 69.4 ± 5.0%, p = NS or MO 10.7 ± 4.8% vs 11.4 ± 4.8%, p = NS, but apyrase prolonged the post-ischemic reactive hyperemia.

ConclusionApyrase treatment according to a clinically applicable protocol, with administration of apyrase after induction of ischemia, does not reduce myocardial infarct size or microvascular obstruction.

Electronic supplementary materialThe online version of this article doi:10.1186-1471-2261-10-1 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Jesper van der Pals - Sasha Koul - Michael I Götberg - Göran K Olivecrona - Martin Ugander - Mikael Kanski - Andreas Ot

Fuente: https://link.springer.com/



DESCARGAR PDF




Documentos relacionados